Literature DB >> 31665726

Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts.

Sophie V Eastwood1, Nishi Chaturvedi2, Naveed Sattar3, Paul I Welsh3, Alun D Hughes2, Therese Tillin2.   

Abstract

BACKGROUND: Evidence is limited on ethnic differences in associations between kidney function markers and mortality or cardiovascular disease (CVD).
METHODS: Baseline cross-sectional analysis and longitudinal follow-up study of a UK population-based cohort of 1,116 Europeans and 1,104 South Asians of predominantly Indian descent, age 52 ± 7 years at baseline (1988-1991). Kidney function was estimated using Cystatin C and creatinine-based chronic kidney disease (CKD) Epidemiology Collaboration estimated glomerular filtration rate (eGFR) equations, and urinary albumin-creatinine ratio (ACR). Mortality was captured at 27 years, and incident CVD at 22 years, from death certification, medical records and participant report. Longitudinal associations between eGFR/ACR and mortality/incident CVD were examined using Cox models.
RESULTS: eGFRcys was lower and ACR higher in South Asians than Europeans. eGFRcys and -eGFRcreat were more strongly associated with outcomes in Europeans than South Asians. Conversely, associations between ACR and outcomes were greater in South Asians than Europeans, for example, for CVD mortality: HRs (95% CI) adjusted for CVD risk factors and ACR/eGFRcys as appropriate, p for ethnicity interaction: eGFRcys: Europeans: 0.76 (0.62-0.92), South Asians: 0.92 (0.78-1.07), p = 0.05, eGFRcreat: Europeans 0.81 (0.67-0.99), South Asians 1.18 (0.97-1.41), p = 0.002, ACR: -Europeans: 1.24 (1.08-1.42), South Asians: 1.39 (1.25-1.57), p= 0.23. Addition of all CKD measures to a standard CVD risk factor model modestly improved prediction capability in -Europeans; in South Asians only ACR contributed to improvement.
CONCLUSIONS: Strong associations between ACR and outcomes in South Asians of predominantly Indian origin, and null associations for eGFRcys and eGFRcreat, suggest that ACR may have greater utility in CVD risk prediction in South Asians. Further work is needed to validate these -findings. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cardiovascular disease; Estimated glomerular filtration rate; Ethnic differences; Mortality; Urinary albumin-creatinine ratio

Mesh:

Substances:

Year:  2019        PMID: 31665726      PMCID: PMC6892637          DOI: 10.1159/000503873

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  38 in total

1.  Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients.

Authors:  Sean J Barbour; Lee Er; Ognjenka Djurdjev; Mohamud Karim; Adeera Levin
Journal:  Nephrol Dial Transplant       Date:  2010-04-05       Impact factor: 5.992

Review 2.  Biomarkers in chronic kidney disease, from kidney function to kidney damage.

Authors:  Salvador Lopez-Giacoman; Magdalena Madero
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction.

Authors:  Alex Chang; Holly Kramer
Journal:  Nephron Clin Pract       Date:  2011-07-28

4.  Microalbuminuria and coronary heart disease risk in an ethnically diverse UK population: a prospective cohort study.

Authors:  Therese Tillin; Nita Forouhi; Paul McKeigue; Nish Chaturvedi
Journal:  J Am Soc Nephrol       Date:  2005-10-05       Impact factor: 10.121

5.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

6.  Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser.

Authors:  E M Kearney; J N Mount; G F Watts; B M Slavin; P R Kind
Journal:  J Clin Pathol       Date:  1987-04       Impact factor: 3.411

7.  Estimating glomerular filtration rates by use of both cystatin C and standardized serum creatinine avoids ethnicity coefficients in Asian patients with chronic kidney disease.

Authors:  Boon Wee Teo; Hui Xu; Danhua Wang; Jialiang Li; Arvind Kumar Sinha; Borys Shuter; Sunil Sethi; Evan J C Lee
Journal:  Clin Chem       Date:  2011-12-28       Impact factor: 8.327

8.  Why is there so much end-stage renal failure of undetermined cause in UK Indo-Asians?

Authors:  S Ball; J Lloyd; T Cairns; T Cook; A Palmer; V Cattell; D Taube
Journal:  QJM       Date:  2001-04

9.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

10.  Progression of chronic kidney disease in a multi-ethnic community cohort of patients with diabetes mellitus.

Authors:  G Dreyer; S Hull; R Mathur; A Chesser; M M Yaqoob
Journal:  Diabet Med       Date:  2013-04-20       Impact factor: 4.359

View more
  2 in total

1.  Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.

Authors:  Malcolm West; Adrienne Kirby; Ralph A Stewart; Stefan Blankenberg; David Sullivan; Harvey D White; David Hunt; Ian Marschner; Edward Janus; Leonard Kritharides; Gerald F Watts; John Simes; Andrew M Tonkin
Journal:  J Am Heart Assoc       Date:  2022-02-18       Impact factor: 5.501

2.  American Indian chronic Renal insufficiency cohort study (AI-CRIC study).

Authors:  Mark L Unruh; Soraya Arzhan; Harold I Feldman; Helen C Looker; Robert G Nelson; Thomas Faber; David Johnson; Linda Son-Stone; Vernon S Pankratz; Larissa Myaskovsky; Vallabh O Shah
Journal:  BMC Nephrol       Date:  2020-07-22       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.